BLU-945

BLU-945 is a potent, highly selective, reversible and orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs). BLU-945 can effectively inhibit EGFR with L858R and/or exon 19 deletion mutation, T790M mutation and C797S mutation.


Cat. No.: EX-A6018	Purity: >99.5% (new batch)

	Chemical structure of BLU-945

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
100mg	285	In-stock
250mg	450	In-stock
500mg	600	In-stock
1g	900	In-stock
5g	2900	In-stock
10g	4450	In-stock

Send PO to E-mail:order@excenen.com; or Fax:+86 020 81619670

Discount Request


Synonyms	BLU945
CAS No.	2660250-10-0
Purity	>99.5% (new batch)
Formula	C28H37FN6O3S
Mol Weight	556.695
Appearance	solid powder
Solubility	Soluble in DMSO
Shelf Life	>2 years if stored properly
Storage	Powder -20℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Meredith S Eno, et al. Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer. J Med Chem. 2022 Jul 28;65(14):9662-9677. [2]. Sun Min Lim, et al. BLU-945, a fourth-generation, potent and highly selective epidermal growth factor receptor tyrosine kinase inhibitor with intracranial activity, demonstrates robust in vivo anti-tumor activity in models of osimertinib-resistant non-small cell lung cancer. [3]. John Emmerson Campbell, et al. Inhibitors of mutant forms of egfr. Patent WO2021133809A1. [4]. Elaine Shum. et al. A phase 1/2 study of BLU-945 in patients with common activating EGFRmutant non-small cell lung cancer (NSCLC) (SYMPHONY trial-in-progress)
Data Sheet	Data sheet of BLU-945
CoA	CoA of BLU-945
SDS	SDS of BLU-945


		Search